Adherence to Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma.

ABSTRACT:

Introduction

One of the most common orally administered antimyeloma agents, lenalidomide, has significantly improved outcomes in multiple myeloma, including in older patients. However, despite its utilization and cost, the rates and factors related to adherence to lenalidomide in older adults with newly diagnosed multiple myeloma remain unknown.

Patients and methods

Data were collected from adults with newly diagnosed multiple myeloma over age 65 years being treated with lenalidomide therapy between the years 2007 and 2014 in the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked databases. Adherence was measured as medication possession ratio (MPR), which was defined as the ratio of the number of days the patient had pills in their possession to the number o

SUBMITTER: Mian H 

PROVIDER: S-EPMC7564009 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature